Abstract: Disclosed herein are compounds that target SMARCA2, SMARCA4 or BRM, causing their degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

Abstract: Optoelectronic structures and methods of assembly are described. In an embodiment, an optoelectronic structure includes a frontplane directly bonded to a backplane, and a cover window attached to the frontplane so that a cavity forms between the cover window and an optical layer of the frontplane. In an embodiment, the width of the cover window is less than the width of the backplane. In an embodiment, the width of the cover window is equal to the width of the backplane.

Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.

Abstract: Provided herein are bifunctional compounds with a moiety or domain that is a binder of the ubiquitin receptor RPN13 and another moiety or domain that is a binder of a target protein DOT1L to induce degradation of DOT1L. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases, such as cancers). Provided also are methods of inducing the degradation of DOT1L by administering a bifunctional compound or composition described herein, wherein one domain of the bifunctional compound is a binder of the ubiquitin receptor RPN13 and another domain of the compound is a binder of the target protein DOT1L in a subject.

Abstract: An electronic device may include a display having a monolithic array of light-emitting diodes mounted to a surface of a substrate layer. The diodes may include contact pads. Driver circuitry may independently drive each of the diodes in the array using drive signals. The driver circuitry may be formed on a driver integrated circuit. Bond pads may be formed on a surface of the integrated circuit. Copper pillars may be grown on the bond pads. In another suitable arrangement, the driver circuitry may be formed on a driver printed circuit board coupled to an interposer by a flexible printed circuit. The interposer may include bond pads and copper pillars grown on the bond pads. The contact pads on each of the diodes may be simultaneously bonded to the copper pillars. A surface of the substrate layer may be patterned to form light redirecting elements if desired.

Abstract: An electronic device such as a voice-controlled speaker device may have a cylindrical shape. The electronic device may include a housing, a speaker in the housing configured to emit sound, and a display in the housing. The display may include a substrate, light-emitting components mounted on the substrate, an opaque support structure mounted on the substrate, a diffuser that is mounted to the opaque support structure and that overlaps the light-emitting components, a display cover layer that overlaps the diffuser, and foam that is interposed between the opaque support structure and the display cover layer. The light-emitting components may be arranged in groups that have the same layout and orientations that vary as a function of angular position relative to the center of the display. The foam and/or an adhesive layer may be formed from two or more discrete pieces that have footprints with complementary protrusions.

Abstract: Disclosed are bispecific compounds (degraders) that target EP300/CBP for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

Abstract: Disclosed herein are compounds that target SMARCA2 and SMARCA4, causing their degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

Abstract: Disclosed are bifunctional compounds (degraders) that target HAT EP300 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hedgehog (Hh) signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: Disclosed are bifunctional compounds (degraders) that target HAT EP300 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

Abstract: A display may include light-emitting diode (LED) pixels. Each LED pixel may include both narrow-viewing-angle subpixels and wide-viewing-angle subpixels. Each LED pixel may include driver circuits that each drive a narrow-viewing-angle subpixel and a wide-viewing-angle subpixel of the same color. An emission logic circuit may direct a drive current from a drive circuit to one or both of a narrow-viewing-angle subpixel and a wide-viewing-angle subpixel of the same color. To correct for off-axis color shift, a pixel may include a green subpixel with two or more overlapping microlenses, a blue subpixel with two or more overlapping microlenses, and a red subpixel without any overlapping microlenses.

Abstract: An electronic device may include a projection display that has a high transparency when the display is turned off. The high off-state transparency may create the appearance of the display being invisible in the off-state, which may be desirable in certain electronic devices. The projection display may include an adjustable diffuser, a spatial light modulator that projects images onto the adjustable diffuser, a mirror that reflects the images from the spatial light modulator to the adjustable diffuser, and a light source that provides light to the spatial light modulator. The projection display may also include an adjustable opacity layer that is controlled based on detected ambient light levels. The projection display may also include an adjustable reflectivity layer. The adjustable diffuser and/or light source may be pixelated to increase contrast in the projection display.

Abstract: A display may include an array of pixels such as light-emitting diode pixels. The circular polarizer may be omitted from the display to increase efficiency. A polarizer-free display may use other non-polarizer techniques to mitigate reflections of ambient light and mitigate associated diffraction artifacts. The polarizer-free display may include a black matrix, color filter element, or pixel definition layer with tapered surfaces to make changes in reflectance associated with the subpixels more gradual. Instead or in addition, a subpixel may have a footprint with one or more protrusions. Instead or in addition, different pixels may have subpixels with different elliptical footprints and/or different footprints with protrusions. Instead or in addition, the polarizer-free display may include color filter elements with concave upper surfaces. Instead or in addition, the polarizer-free display may include subpixels with varying anode heights.

Abstract: A display may include an array of pixels covered by lenticular lenses. The lenticular lenses may cause expansion of light primarily in a horizontal direction. To improve the perceived resolution of the display, the horizontal resolution of the pixels on the display may be increased. In one possible layout, each pixel includes one red sub-pixel, one blue sub-pixel, and one green sub-pixel. The sub-pixels may be non-square rectangular. The sub-pixels may be the same size or may have the same widths and different heights. Each pixel may be asymmetric about a horizontal axis. In a given row, the pixels may alternate between first and second layouts. The second layout may be a vertically flipped version of the first layout.

Abstract: A dielectric barrier discharge plasma generator includes a ground electrode and a high voltage electrode which are configured to form a circuit to receive a power input for plasma generation, a dielectric barrier having a first surface attached to the high voltage electrode, and a second surface facing the ground electrode, and discharge gap being formed between the second surface of the dielectric barrier and the ground electrode for plasma generation, and a resiliently deformable mechanism operative to bias the high voltage electrode against the first surface of the dielectric barrier.

Abstract: A display may have a pixel array such as a liquid crystal pixel array. The pixel array may be illuminated with backlight illumination from a direct-lit backlight unit. The backlight unit may include an array of light-emitting diodes on a printed circuit board. The backlight unit may include first, second, and third light spreading layers formed over the array of light-emitting diodes. A color conversion layer may be formed over the first, second, and third light spreading layers. First and second brightness enhancement films may be formed over the color conversion layer.

Abstract: An electronic display including a display panel that includes a plurality of display pixels having non-uniform luminance characteristics. The electronic display also includes pixel uniformity correction circuitry configured to compensate for the non-uniform luminance characteristics of the display pixels based on a pixel luminance correction factor selected based on pixel group luminance error patterns corresponding to locations of the display pixels.

Abstract: Provided herein are bifunctional compounds with a moiety or domain that is a binder of the ubiquitin receptor RPN13 and another moiety or domain that is a binder of a target protein DOT1L to induce degradation of DOT1L. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases, such as cancers). Provided also are methods of inducing the degradation of DOT1L by administering a bifunctional compound or composition described herein, wherein one domain of the bifunctional compound is a binder of the ubiquitin receptor RPN13 and another domain of the compound is a binder of the target protein DOT1L in a subject.

Abstract: A display may include a color filter layer, a liquid crystal layer, and a thin-film transistor layer. A camera window may be formed in the display to accommodate a camera. The camera window may be formed by creating a notch in the thin-film transistor layer that extends inwardly from the edge of the thin-film transistor layer. The notch may be formed by scribing the thin-film transistor layer around the notch location and breaking away a portion of the thin-film transistor layer. A camera window may also be formed by grinding a hole in the display. The hole may penetrate partway into the thin-film transistor layer, may penetrate through the transistor layer but not into the color filter layer, or may pass through the thin-film transistor layer and partly into the color filter layer.